QIAGEN N.V. (QGEN) Forms Wedge Down; Strong Momentum for Sellers


The stock of QIAGEN N.V. (QGEN) formed a down wedge with $34.21 target or 3.00 % below today’s $35.27 share price. The 7 months wedge indicates high risk for the $7.98 billion company. If the $34.21 price target is reached, the company will be worth $239.40M less.
Falling wedges are poor performers for bullish breakouts and are tricky moments to trade. Investors must be aware that the break even failure rate for up or down breakouts is: 11% and 15%. The average rise is 32% and the decline is 15%. The falling wedges has high throwback and pullback rate: 56%, 69% and the percent of wedges meeting target is not very high.

The stock decreased 0.45% or $0.16 during the last trading session, reaching $35.27. About 418,102 shares traded. QIAGEN N.V. (NYSE:QGEN) has risen 18.00% since December 6, 2017 and is uptrending. It has outperformed by 2.38% the S&P500.

Analysts await QIAGEN N.V. (NYSE:QGEN) to report earnings on January, 30. They expect $0.40 EPS, down 6.98 % or $0.03 from last year’s $0.43 per share. QGEN’s profit will be $90.50 million for 22.04 P/E if the $0.40 EPS becomes a reality. After $0.35 actual EPS reported by QIAGEN N.V. for the previous quarter, Wall Street now forecasts 14.29 % EPS growth.

More notable recent QIAGEN N.V. (NYSE:QGEN) news were published by: Fool.com which released: “Qiagen Starts Slowly but Is On Track – The Motley Fool” on May 07, 2018, also Fool.com with their article: “Qiagen NV Meets Its Own 3rd-Quarter Expectations – The Motley Fool” published on November 13, 2017, Businesswire.com published: “QIAGEN announces 20-F annual report filing for 2017 results – Business Wire” on March 06, 2018. More interesting news about QIAGEN N.V. (NYSE:QGEN) were released by: Businesswire.com and their article: “QIAGEN N.V. to Report Second Quarter and First Half of 2018 Results – Business Wire” published on July 17, 2018 as well as Businesswire.com‘s news article titled: “QIAGEN and Natera Partner to Develop Cutting-Edge Genetic Testing Assays for Use on QIAGEN’s GeneReader NGS System – Business Wire” with publication date: March 12, 2018.

QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company has market cap of $7.98 billion. It offers sample technologies for plasmid deoxyribonucleic acid purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, and library preparation for sequencing applications; and assay technology solutions. It has a 92.6 P/E ratio. The firm provides Ingenuity Variant Analysis, a cloud platform that interprets data from next-generation sequencing (NGS) analysis; QIAGEN Clinical Insight, an evidence decision support solution; CLC Genomics Workbench for the analysis and visualization of data from various NGS platforms; and GeneGlobe, a Web portal that enables researchers to search and select gene-and pathway-specific solutions from pre-designed and custom PCR assay kits, NGS assay panels, and other products.

QIAGEN N.V. (NYSE:QGEN) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.